Tag: BRAF/MEK
Phase II Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory...
Positive, mature, results from a Phase II study of glembatumumab vedotin (Celldex Therapeutics) in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK...
Glembatumumab vedotin Shows Encouraging anti-tumor Activity Checkpoint Inhibitor-refractory Metastatic Melanoma
Results from a phase II trial presented in a poster at the annual meeting of the European Society of Medical Oncology, held in Copenhagen,...
